Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Magle Chemoswed Holding ABFRA:52X 40 Debt-to-Equity is 1.32 as of Jun. 2026, which is 267% above its 10-year median of 0.36. GuruFocus rates FRA:52X with a GF Score™ of 40/100 and a GF Value™ of €1.56. The stock has 6 warning signs investors should review. Among 954 Biotechnology companies, Magle Chemoswed Holding AB ranks worse than 90.46% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Magle Chemoswed Holding AB's Debt-to-Equity or its related term are showing as below:
FRA:52X'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.36 Max: 1.32
Current: 1.32
During the past 8 years, the highest Debt-to-Equity Ratio of Magle Chemoswed Holding AB was 1.32. The lowest was 0.04. And the median was 0.36.
FRA:52X's Debt-to-Equity is ranked worse than 90.46% of 954
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:52X: 1.32
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Magle Chemoswed Holding AB Debt-to-Equity Related Terms
Magle Chemoswed Holding AB Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:52X vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Magle Chemoswed Holding AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Magle Chemoswed Holding AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Magle Chemoswed Holding AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Magle Chemoswed Holding AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Magle Chemoswed Holding AB (FRA:52X) has a Debt-to-Equity of 1.32 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Magle Chemoswed Holding AB and its competitors. This is 267% above median its historical median of 0.36. Over the past decade, Magle Chemoswed Holding AB's Debt-to-Equity has ranged from 0.04 to 1.32. According to the industry distribution chart, Magle Chemoswed Holding AB ranks #863 out of 954 companies in the Biotechnology industry, placing it in the top 90.5%.
Is Magle Chemoswed Holding AB's Debt-to-Equity too high?
Magle Chemoswed Holding AB's current Debt-to-Equity of 1.32 is 267% above median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 1.32. The Biotechnology industry median Debt-to-Equity is 0.16. Magle Chemoswed Holding AB's value of 1.32 is 725% above this industry median. Based on the distribution chart, Magle Chemoswed Holding AB ranks #863 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Magle Chemoswed Holding AB has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Magle Chemoswed Holding AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Magle Chemoswed Holding AB ranks #863 out of 954 companies for Debt-to-Equity. This places Magle Chemoswed Holding AB in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Magle Chemoswed Holding AB's value of 1.32 is 725% above this benchmark. Historically, Magle Chemoswed Holding AB's own Debt-to-Equity has ranged from 0.04 to 1.32 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 0.16, Magle Chemoswed Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Magle Chemoswed Holding AB's current Debt-to-Equity of 1.32 is 725% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Magle Chemoswed Holding AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Magle Chemoswed Holding AB's current Debt-to-Equity is 1.32, which is 267% above median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Magle Chemoswed Holding AB stock overvalued right now?
Magle Chemoswed Holding AB (FRA:52X) has a current Debt-to-Equity of 1.32. The stock's GF Value™ is €1.56, compared to a current price of €0.03 — trading 98.2% below its estimated fair value. The current Debt-to-Equity is 1.32, which is 267% above median its 10-year median of 0.36 and 725% above the Biotechnology industry median of 0.16. Magle Chemoswed Holding AB's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Magle Chemoswed Holding AB (FRA:52X), the current Debt-to-Equity is 1.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Magle Chemoswed Holding AB (FRA:52X) Overvalued in 2026?
Based on GuruFocus' analysis, Magle Chemoswed Holding AB stock appears to be undervalued.
The current stock price of €0.03 is trading 98.2% below its estimated GF Value™ of €1.56.
Key valuation signals for FRA:52X:
Debt-to-Equity: 1.32 (267% above median its 10-year median of 0.36)
GF Value™: €1.56 vs. price of €0.03 (98.2% below fair value)
Industry Position: 725% above the Biotechnology median (#863 of 954)
No single metric tells the full story. See the FRA:52X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.
40GF Score
Get the complete analysis for FRA:52X
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:52X has been successfully added to your 
